On March 18, 2026 Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, reported upcoming presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place April 17-22 in San Diego.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentations will highlight progress across Circle Pharma’s cyclin inhibitor programs and its MXMO platform, including preclinical findings and an oral plenary highlighting early clinical activity for CID-078, a first-in-class, orally bioavailable macrocyclic cyclin A/B RxL inhibitor currently being evaluated in a Phase 1 clinical trial for patients with advanced solid tumors.
Details of the presentations are as follows:
Oral Presentations
Title: Early clinical activity from the phase 1 evaluation of CID-078, a novel Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors
Session Title: Clinical Trials Plenary Session: New Frontiers in Precision Oncology
Date & Time: Sunday, April 19, 1:00-3:00 p.m. PST
Presenter: Afshin Dowlati, M.D.
Title: Discovery of CID-078, a first-in-class oral macrocycle cyclin A/B-RxL inhibitor, for the treatment of cancers with RB1 loss or hyperactivated E2F
Session Title: New Drugs on the Horizon: Part 3
Date & Time: Monday, April 20, 10:15-11:45 a.m. PST
Presenter: Marie Evangelista, Ph.D.
Poster Presentation
Title: Orally Bioavailable Peptide Macrocycles Disrupting Intracellular Protein-Protein Interactions: Selective Inhibitors of the RxL-binding Site of Cyclin Family Proteins
Session Title: Chemistry to the Clinic Part 3 of 4: Novel Modalities, Targets, and Mechanisms in Drugging Oncogenic Pathways
Date & Time: Saturday, April 18, 12:30-2:00 p.m. PST
Presenter: Justin Shapiro, Ph.D.
About CID-078, Circle Pharma’s Oral Cyclin A/B RxL Inhibitor Program
CID-078 is an orally bioavailable macrocycle with dual activity blocking protein-protein interactions between both cyclins A and B and key substrates that bind to them via conserved RxL motifs. CID-078 selectively targets tumor cells with oncogenic alterations that cause cell cycle dysregulation, including alterations in the tumor suppressor RB1. In preclinical studies, Circle Pharma’s cyclin A/B RxL inhibitors have been shown to potently and selectively disrupt the protein-to-protein interaction between cyclins A and B and their key substrates and modulators, including E2F (a substrate of cyclin A) and MYT1 (a modulator of cyclin B). Preclinical studies have demonstrated the ability of these cyclin A/B RxL inhibitors to cause single-agent tumor regressions in multiple in vivo models. A multicenter Phase 1 clinical trial (NCT06577987) is currently enrolling patients with advanced solid tumors harboring RB1 alterations.
(Press release, Circle Pharma, MAR 18, 2026, View Source [SID1234663698])